|
|
2017 Featured Talks » Epigenetics of GBM Cancer Stem Cells
Epigenetics of GBM Cancer Stem Cells
Laure Escoubet, PhD
Celgene
Part 1
Part 2
Laure Escoubet, PhD
Director, Head of Epigenetic Drug Discovery
Celgene
Dr Laure Escoubet joined Celgene in 2006 bringing her epigenetic expertise to bear immediately with the identification and validation of promising epigenetic targets in cancer through a functional genomic screen, effectively launching Celgene’s epigenetic drug discovery efforts.
Laure has been supported the pre-clinical development of small molecule inhibitors and provided expertise to the external epigenetic AGIOS, Epizyme and Quanticel collaborations. She designed the first comprehensive epigenetic profiling of cancer stem cells, allowing the identification of proprietary transcriptional and epigenetic targets.
Prior to Celgene, Laure did her post-doctoral training at the University of California, San Diego, in the laboratory of Christopher K. Glass. There, she pioneered genome-wide epigenetic studies in inflammation, investigating the regulation of chromatin modifications in macrophages and the orchestrated program that controls gene expression in these cells.
Laure received her PhD in Human Pathophysiology from the University Paul Sabatier in Toulouse, France.
|
